Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 - Episode 4
Review of the COMMANDS Trial
The experts examine the COMMANDS trial, which assessed luspatercept in lower-risk myelodysplastic syndrome patients, detailing the trial's design, participant groups, and key outcome measures.
- Dr Garcia-Manero: Briefly summarize the COMMANDS trial, evaluating luspatercept in patients with lower-risk MDS (Platzbecker U et al. Lancet Onco 2023).
- Briefly comment on the study design, patient population, and primary/secondary endpoints.